Department of Ophthalmology at St. Franziskus Hospital, University Duisburg-Essen, Hohenzollernring 74, 48145, Muenster, Germany.
Graefes Arch Clin Exp Ophthalmol. 2010 Nov;248(11):1531-51. doi: 10.1007/s00417-010-1485-8. Epub 2010 Aug 25.
Endogenous uveitis is a sight-threatening disease. In addition to corticosteroids, immunosuppressive agents are commonly used to treat patients with severe course. Immunosuppressive drugs act nonspecifically, rather than providing a specific interaction with the critical pathogenetic pathways of uveitis. Better knowledge of the basic mechanisms underlying uveitis and of the molecules that are important for regulating inflammation has helped to create new and more specific treatment approaches. Biological therapy for inflammatory diseases employs substances that interfere with specific molecules or pathways induced in the body during the inflammatory process.
This review gives an overview on molecules that play a critical role in the pathogenetic process of uveitis, as has been observed in patients or the respective animal models, and summarizes the current experience with biologicals for the treatment of uveitis refractive to conventional immunosuppressives.
内源性葡萄膜炎是一种威胁视力的疾病。除了皮质类固醇外，免疫抑制剂通常也被用于治疗病情严重的患者。免疫抑制剂的作用是非特异性的，而不是与葡萄膜炎的关键致病途径进行特异性相互作用。更好地了解葡萄膜炎的基本机制以及对炎症调节很重要的分子，有助于创造新的、更具特异性的治疗方法。用于治疗炎症性疾病的生物疗法采用的是干扰体内炎症过程中诱导产生的特定分子或途径的物质。
本综述概述了在患者或相应的动物模型中观察到的在葡萄膜炎发病过程中起关键作用的分子，并总结了生物制剂治疗对传统免疫抑制剂反应不佳的葡萄膜炎的现有经验。
